EUCTR2013-004535-72-IE进行中（未招募）1 期
A prospective, single-centre, cohort study to determine the pharmacokinetic and pharmacodynamic parameters of teicoplanin in adult patients with haematological malignancy. - PK/PD study of teicoplanin in adults with haematological malignancy.
Tallaght Hospital, Dublin 24, Ireland0 个研究点开始时间: 2013年11月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Haematological malignancy; 18 years or above; treated with teicoplanin for at least 3 days; suitable intravenous or intra-arterial access; written informed consent obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Consent not obtained; age <18 years; administered teicoplanin for <3 days; limited or no IV or intra-arterial access; receiving renal replacement therapy; admittance to the Intensive Care Unit.
研究者
相似试验
已完成
不适用
Storage, transport and incubation for N. gonorrhoea sampleseisseria gonorrhoea infectionInfections and InfestationsISRCTN55795067orth Cumbria Integrated Care NHS Foundation Trust64
已完成
不适用
A Prospective study to determine gut microbiota composition in Indian children with history of antibiotic usage compared to those who did not use antibiotic by stool analysisCTRI/2021/05/033685Dr Reddys Laboratories Ltd54
已完成
不适用
Assessing the clinical efficacy of the Pericapsular Nerve Group (PENG) block in hip fracture surgeryneck of femur fractureInjuries and Accidents - FracturesAnaesthesiology - Pain managementACTRN12620000370909Flinders Medical Centre28
已完成
不适用
Relationship between digit ratio and postoperative nausea and vomitingpostoperative nausea and vomitingJPRN-UMIN000048615Jichi Medical University Saitama Medical Center882
尚未招募
4 期
Clinical study to asses the CT angiography results following the use of the MeRes100 Sirolimus-Eluting Bioresorbable Vascular Scaffold System in patients with coronary artery disease.CTRI/2024/04/066128Dr Keyur Parikh